Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$2.83 - $3.87 $10,337 - $14,137
3,653 New
3,653 $10,000
Q2 2022

Aug 12, 2022

SELL
$2.13 - $5.38 $2,534 - $6,402
-1,190 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$29.44 - $43.74 $7,301 - $10,847
248 Added 26.33%
1,190 $35,000
Q1 2021

May 14, 2021

BUY
$32.41 - $70.91 $30,530 - $66,797
942 New
942 $48,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $59.2M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.